TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers at Michigan Medicine report that DT-109 improved metabolic dysfunction-associated steatohepatitis (MASH) in mice and nonhuman primates by reducing harmful gut bacteria and protecting the intestinal barrier. The findings, published in The Journal of Clinical Investigation, are preclinical; the report does not establish that the drug works in people.
Researchers at Michigan Medicine report that experimental compound DT-109 reversed MASH in animal studies by reducing harmful gut bacteria and strengthening the intestinal barrier. The study, published in The Journal of Clinical Investigation, describes a potential treatment strategy for a serious fatty liver disease, but the findings are preclinical and do not show that DT-109 treats people.
The research examined how DT-109, a glycine-based tripeptide, affects the relationship between the gut and liver. The team had previously found that the compound could improve MASH in animals; this study investigates how it may do so. Researchers linked excessive growth of Clostridium perfringens—a bacterium that produces ammonia in the intestines—to damage to the gut’s protective lining.
When that lining is weakened, microbial products can pass into the bloodstream and reach the liver, where they may contribute to inflammation. The study also describes excessive activation of CD8+ T cells, immune cells that can add to inflammatory damage when overactive. In experiments involving mice and nonhuman primates, DT-109 reduced levels of the bacterium and intestinal ammonia, and helped limit the passage of harmful substances beyond the gut.
In nonhuman primates, the researchers reported less liver inflammation and lower MASH severity. The source does not provide trial results in humans, patient outcomes, or a clinical dose. The findings establish an animal-study result, not a proven human treatment or a basis for patients to use the compound.
A Gut-Based Route to Liver Protection
MASH involves excess fat in the liver along with inflammation and cellular damage. It can progress to cirrhosis, liver cancer, or liver failure, while effective treatment options remain limited, according to the report. The study’s central significance is that it points to gut bacteria and the intestinal barrier as possible contributors to liver injury—and potential targets for intervention.
The findings may help explain why changes outside the liver can affect liver disease: substances absorbed from the intestines travel to the liver, creating a biological link known as the gut-liver axis. If a similar mechanism is shown in people, treatment aimed at the gut could complement approaches focused directly on liver damage. That possibility remains a research implication, not a demonstrated clinical benefit.
The report says MASH affects about 7% of the world’s population. That estimate makes the search for additional approaches relevant to many people, but it does not mean DT-109 is available or suitable for them. Results in animals, including nonhuman primates, cannot by themselves establish safety or effectiveness in humans.
As an affiliate, we earn on qualifying purchases.
How the Gut-Liver Link Emerged
The research team’s earlier animal work had indicated that DT-109 could improve MASH, but the mechanism was not clear. The new study offers a proposed sequence: growth of ammonia-producing gut bacteria may damage the intestinal barrier; microbial products can then move into circulation and reach the liver, where they contribute to inflammatory responses.
DT-109 is described as acting primarily in the gastrointestinal tract, even though the reported benefits include changes in the liver. The source also notes prior research in nonhuman primates in which DT-109 reduced atherosclerotic plaque formation and prevented vascular calcification. Those earlier findings concern separate cardiovascular outcomes and do not establish that the compound can treat cardiovascular disease in people.
“We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression.”
— Eugene Chen, senior author and professor of cardiovascular medicine at the University of Michigan Medical School
As an affiliate, we earn on qualifying purchases.
Human Evidence Is Still Missing
The reported findings come from animal models. The source does not say whether human clinical trials have begun, when they might start, or whether DT-109 has been tested for safety and effectiveness in people. It also does not provide enough detail here to assess the study’s sample sizes, treatment duration, or how durable the reported improvements were.
It remains unclear whether the same bacterial changes and barrier effects occur in human MASH, whether any benefit would extend to different stages of disease, and what risks the compound might carry. The term “reversed” in the report refers to results in animal studies; it should not be read as evidence that the disease has been reversed in human patients.
As an affiliate, we earn on qualifying purchases.
Clinical Testing Would Be the Next Test
The next key evidence would be details on whether DT-109 advances into human trials and, if it does, the results of carefully controlled studies measuring safety and liver outcomes. Until such evidence is reported, the animal findings provide a rationale for further research rather than a treatment recommendation.
Researchers will also need to clarify how the compound affects the gut microbiome and intestinal barrier over time, and whether those changes account for the improvements observed in animals. The source does not give a clinical development schedule, so the timing of any human testing remains unknown.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is DT-109?
DT-109 is an experimental glycine-based tripeptide studied by Michigan Medicine researchers. The report describes it as acting mainly in the gastrointestinal tract.
Did DT-109 reverse fatty liver disease in people?
No human results are reported. The study found improvements in mice and nonhuman primates, so effectiveness in people has not been established.
How is the gut thought to affect MASH?
The study links ammonia-producing gut bacteria to damage to the intestinal barrier. That damage may allow microbial products to reach the liver and contribute to inflammation and liver injury.
When could DT-109 become available?
The source does not state whether human trials have begun or provide a timeline for approval or availability. Further clinical testing would be needed to establish safety and effectiveness in people.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
